TP53-mut MCL — predicts chemoimmuno failure. Acalabrutinib + rituximab (TRIANGLE / ECHO)...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-MCL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MCL |
| Sources | SRC-CIVIC SRC-ESMO-MCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-MCL |
| ESCAT tier | IIA |
| Recommended combinations | acalabrutinib + rituximab (1L), ibrutinib + rituximab + venetoclax (R/R), CAR-T brexu-cel (R/R) |
| Evidence summary | TP53-mut MCL — predicts chemoimmuno failure. Acalabrutinib + rituximab (TRIANGLE / ECHO) preferred over R-CHOP/R-DHAP+autoSCT regardless of fitness. |
Notes
ESCAT IIA. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.